Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combination of NMDA-enhancing and Antioxidant Treatments for Schizophrenia
NCT04959201Phase 2Recruiting
- Sponsor
- China Medical University Hospital
- Start
- Nov 2020
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in schizophrenia (2 arms), sponsored by China Medical University Hospital. Primary endpoint: Positive and Negative Syndrome Scale at 12 weeks. Started Nov 2020; status: recruiting.
02
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT04959201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04959201.